Executive Summary
Vectura Group plc?s principal focus is the development of a range of inhaled drugs for the treatment of both lung diseases and other conditions where optimised delivery via the lungs can provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies. Vectura?s strategy is to combine its proprietary, innovative, pulmonary formulation and device technologies (PowderHale(R), Aspirair(R) and GyroHaler (R)) with existing, off-patent drugs either for use in new indications or to provide inhalation as an improved route of administration. The Company seeks to license its lead products to pharmaceutical companies with established sales and marketing infrastructures for the later stages of development and for commercialisation, typically prior to Phase III clinical development. In addition to its own pharmaceutical products, Vectura operates a well established Pharmaceutical Development Services business that undertakes contract development work for other pharmaceutical companies. Vectura has also licensed some of its technologies in certain fields to other pharmaceutical companies. These activities generate positive cash flows that are available for investment in Vectura?s own development projects. These activities also demonstrate Vectura?s acknowledged expertise in applying pulmonary technologies to the creation of innovative pharmaceutical products. The Company has development collaborations with a number of companies, including Novartis, GSK, SkyePharma and Chiesi.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
